Gilead Gets Buy, Amgen Holds: Biopharma Calls Roil Markets
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Discover what are different investing strategies and how they can help you succeed in your investment journey.
18,703 articlesWall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
Navigator (NVGS) 2025 earnings paint a picture of a niche LNG carrier operator balancing utilization, rates and lever...
Loan brokerages are expanding headcount and GCI, but margins are thinning. A new industry look shows why growth often...
Got $10,000 and a goal to generate reliable cash from dividends? This guide shows how to pick the smartest dividend s...
A sharp uptick in Micron's revenue is grabbing attention. This article breaks down what caused the rise, whether it c...
Spotlighting two strong growth names that could exceed Summit Therapeutics in a year. Learn the catalysts, risks, and...
A small group of stocks power long-term wealth, while the majority underperform. This report explains how to find the...
Two strong players define today’s clean energy stock face-off. This guide breaks down how Bloom Energy and Brookfield...
A growing number of savers are adopting a three-bucket income strategy to generate roughly $60,000 a year from divide...
Geopolitical shocks can destabilize oil markets. This guide explains why midstream oil stocks often prove resilient d...
With 2026's COLA at 2.8% and roughly 71 million Social Security beneficiaries, the decision on when to claim continue...
A Colorado resident was drawn into a high-pressure sales pitch for a $1 million fixed indexed annuity, featuring a ph...